Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01376700
Other study ID # 061002
Secondary ID 2011-000410-18
Status Terminated
Phase Phase 3
First received
Last updated
Start date August 26, 2011
Est. completion date November 16, 2012

Study information

Verified date April 2021
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study was to assess if a once-weekly prophylactic regimen of 25 IU/kg ADVATE started at or before 1 year of age and before the onset of a severe bleeding phenotype (ie, joint bleeding), together with the minimization of immunological danger signals, can reduce the incidence rate of inhibitor formation in PUPs with severe and moderately severe hemophilia A.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date November 16, 2012
Est. primary completion date November 16, 2012
Accepts healthy volunteers No
Gender Male
Age group N/A to 1 Year
Eligibility Inclusion Criteria: - Participants with severe and moderately severe hemophilia A (FVIII = 2%) - Participants < 1 year of age - Participants must have = 3 exposure days (EDs) to any FVIII concentrate or FVIII-containing product used for treatment of minor bleeds (bleeds requiring no more than 2 infusions per event), or for preventative or precautionary infusions following possible injury - Participants with prior circumcision are allowed to enroll only if bleeding issues related to circumcision were the cause for the original diagnosis of hemophilia A and no more than 2 EDs of FVIII treatment were required - Adequate venous access (without need for central venous access device (CVAD)-placement) as determined by the physician - Written informed consent from legally authorized representative(s) Exclusion Criteria: - Life-threatening conditions (intracranial hemorrhage, severe trauma) or requirement for surgery at the time of enrollment - Evidence of inhibitor = 0.6 Bethesda Unit (BU) in Nijmegen-modified Bethesda Assay at study start (samples may be retested using lupus-insensitive inhibitor tests to reduce the number of false positive inhibitor test results) - Inherited or acquired hemostatic defect other than hemophilia A - Any clinically significant, chronic disease other than hemophilia A - Known hypersensitivity to ADVATE or any of its constituents - Any planned elective surgery that cannot be postponed until after the first 20 EDs - Participation in the Hemophilia Inhibitor Previously Untreated Patient Study - Application of red blood cell, platelet, or leukocyte concentrates, or plasma - Administration of any medication affecting coagulation or platelet function - Systemic administration of any immunomodulatory drug (eg, chemotherapy, intravenous glucocorticoids) - Participation in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or during the course of this study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Baxalta now part of Shire Baxter Innovations GmbH

Countries where clinical trial is conducted

United States,  Austria,  Bulgaria,  Canada,  Czechia,  Germany,  Lithuania,  Netherlands,  Poland,  Russian Federation,  Serbia,  Spain, 

References & Publications (1)

Auerswald G, Kurnik K, Aledort LM, Chehadeh H, Loew-Baselli A, Steinitz K, Reininger AJ; EPIC clinical study group. The EPIC study: a lesson to learn. Haemophilia. 2015 Sep;21(5):622-8. doi: 10.1111/hae.12666. Epub 2015 Apr 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Severe and Moderately Severe Hemophilia A (FVIII = 2%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (> 5 BU/mL) or - ii. Low FVIII inhibitor titer (=0.6 - =5.0 BU/mL). 50 exposure days to ADVATE
Secondary Number of Participants With Severe Hemophilia A (FVIII = 1%) With Factor VIII (FVIII) Inhibitor Formation Within the First 50 Exposure Days to ADVATE Inhibitor testing will be performed in the central laboratory and a non-zero result must be confirmed in the central laboratory as soon as possible, preferably 1 week after inhibitor testing. Confirmed FVIII inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 Bethesda Units (BU)/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (> 5 BU/mL) or - ii. Low FVIII inhibitor titer (=0.6 - =5.0 BU/mL). 50 exposure days to ADVATE
Secondary Number of Exposure Days of Treatment With Advate Prior to First Positive Factor VIII (FVIII) Confirmed Inhibitor Assessment Confirmed inhibitor is defined as any FVIII inhibitor assay result equal or greater than 0.6 BU/mL confirmed by the central laboratory on 2 consecutive samples, i.e. at least 2 positive inhibitor results (including the first positive inhibitor test, in accordance with the study protocol) assessed as either: - i. High FVIII inhibitor titer (> 5 BU/mL) or - ii. Low FVIII inhibitor titer (=0.6 - =5.0 BU/mL). 50 exposure days to ADVATE
Secondary Number of Participants With Low-titer, High-titer, Transient, and All Factor VIII (FVIII) Inhibitors - High FVIII inhibitor titer (> 5 Bethesda Unit (BU)/mL) - Low FVIII inhibitor titer (=0.6 - =5.0 BU/mL) 50 exposure days to ADVATE
Secondary Number, Type, and Severity of All Bleeds Experienced When Different Prophylactic Dosing Frequencies Are Used (Once or Twice Per Week and Unknown Frequency) Nominal Dosing Frequency: - 1 time per week - 2 times per week - Unknown dosing frequency (UK) Bleeding Type (BT): - Skin - Muscle and Soft Tissue - Mucosal - Joint - Other - Multiple - Total Bleeding severity: - Minor - Moderate - Severe - Total 50 exposure days to ADVATE
Secondary Number and Type of Surgeries - Elective surgery is not allowed during period of first 20 exposure days (EDs) - Peripherally inserted central catheter (PICC) 50 exposure days to ADVATE
Secondary Correlation of Known Risk Factors to Factor VIII (FVIII) Inhibitor Formation 50 exposure days to ADVATE
Secondary Total Factor VIII (FVIII) Consumption by Participant 50 exposure days to ADVATE
Secondary FVIII-Specific Antibody Isotype for All Participants at Study Entry and Every 10 Exposure Days (EDs) 50 exposure days to ADVATE
Secondary Number of Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) at Least Possibly Related to ADVATE Possibly or probably related adverse events 50 exposure days to ADVATE
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1